Chesapeake IRB Announces Acquisition of MaGil IRB
Columbia, Md., June 7, 2017 (Business Wire) – Chesapeake IRB, the technology-enabled independent institutional review board (IRB) serving the clinical research industry, announced it has acquired MaGil IRB, a central IRB located in Rockville, Md.
The MaGil acquisition provides Chesapeake with additional AAHRPP-accredited review capacity and a staff that broadens Chesapeake’s presence for CROs, pharmaceutical companies, and biotech companies. This marks Chesapeake’s fifth acquisition of an AAHRPP-accredited IRB since 2013, further positioning itself as an IRB to support the growth in the clinical research industry.
“Today we are delighted to welcome MaGil IRB to the Chesapeake family,” said Jeff Wendel, president and CEO of Chesapeake. “Together, we are even better positioned to deliver unparalleled human subject protections and oversight and exceptional client service.”
“Joining with Chesapeake allows MaGil customers to benefit from Chesapeake’s innovative cloud-based IRB platform, CIRBI, while continuing the joint mission of safeguarding the rights and welfare of clinical research participants,” said Gil Price, co-founder and CEO of MaGil IRB.
About Chesapeake IRB
Chesapeake IRB, an AAHRPP-accredited company, provides independent IRB submission and review services to pharmaceutical, biotech, and medical device companies, as well as academic medical centers and hospital systems. Its paperless, cloud-based submission and review platform, CIRBI, leads the field and has set the standard in review turnaround time, quality, and document accessibility. Headquartered in Columbia, MD, Chesapeake IRB has offices across the United States and a wholly owned subsidiary, IRB Services, with offices in Toronto and Montreal, Canada. Visit chesapeakeirb.com for more information.
CONTACT:
Lea Studer
SCORR Marketing
308.237.5567
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
